[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]
Views 85
Citations 0
Correction
July 2019

Error in the Figure

JAMA Oncol. 2019;5(7):1070. doi:10.1001/jamaoncol.2019.2255

In the Research Letter titled “Androgen Receptor Burden and Poor Response to Abiraterone or Enzalutamide in TP53 Wild-Type Metastatic Castration-Resistant Prostate Cancer,” which published online May 2, 2019, in JAMA Oncology,1 there was an error in Figure, B. In the Characteristic column under “Number AR perturbations,” the number “3” should be “2.” This article was corrected online.

References
1.
De Laere  B, Rajan  P, Grönberg  H, Dirix  L, Lindberg  J; CORE-ARV-CTC and ProBIO Investigators.  Androgen receptor burden and poor response to abiraterone or enzalutamide in TP53 wild-type metastatic castration-resistant prostate cancer  [published online May 2, 2019].  JAMA Oncol. doi:10.1001/jamaoncol.2019.0869PubMedGoogle Scholar
×